Drugs Made In America Acquisition (DMAA) EBT (2025)

Drugs Made In America Acquisition's (DMAA) quarterly EBT came in at $212958.0 in Q4 2025, down 90.25% on a QoQ basis from $2.2 million in Q3 2025.

Drugs Made In America Acquisition (DMAA) EBT (2025) Analysis & Trends

Drugs Made In America Acquisition (DMAA) has 1 years of EBT data on file, last reported at $212958.0 in Q4 2025.

Quarterly EBT changed N/A year-over-year to $212958.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.9 million (changed N/A YoY) and the FY2025 annual result came in at $5.9 million, up 2222.83% from the prior year.
EBT eased to $212958.0 in Q4 2025, from $2.2 million in the prior quarter.
In the past five years, EBT ranged from a high of $2.3 million in Q2 2025 to a low of $212958.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT (Qtr)
1	Launch Two Acquisition	557.86 Mn	557.86 Mn	-	1.95 Mn
2	Drugs Made In America Acquisition	507.00 Mn	507.00 Mn	-	4.40 Mn
3	Cantor Equity Partners IV	467.55 Mn	467.55 Mn	-	3.92 Mn
4	GP-Act III Acquisition	401.06 Mn	401.06 Mn	-	290,121.00
5	Aldel Financial	397.49 Mn	397.49 Mn	-	2.11 Mn
6	Gores Holdings X	381.05 Mn	380.85 Mn	-	1.88 Mn
7	Agriculture & Natural Solutions Acquisition	377.29 Mn	377.04 Mn	-	-
8	Blue Water Acquisition Corp. III	342.12 Mn	342.08 Mn	-	-197,949.00
9	Berto Acquisition	313.96 Mn	313.81 Mn	-	1.11 Mn
10	Drugs Made In America Acquisition	215.52 Mn	215.52 Mn	-	1.73 Mn

Download Data